Cargando…

Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma

Detalles Bibliográficos
Autores principales:	Axelrod, M, Ou, Z, Brett, L K, Zhang, L, Lopez, E R, Tamayo, A T, Gordon, V, Ford, R J, Williams, M E, Pham, L V, Weber, M J, Wang, M L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918872/ https://www.ncbi.nlm.nih.gov/pubmed/23979520 http://dx.doi.org/10.1038/leu.2013.249

Ejemplares similares

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Mediates the Synergistic Signalling between TLR9 and the B Cell Receptor by Regulating Calcium and Calmodulin
por: Kenny, Elaine F., et al.
Publicado: (2013)

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib
por: Lu, Ziwen, et al.
Publicado: (2022)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
por: Weber, Alexander N. R., et al.
Publicado: (2017)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA
por: Shah, B., et al.
Publicado: (2022)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models
por: Crawford, L J, et al.
Publicado: (2014)

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
por: Rotstein, Dalia L
Publicado: (2022)

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
por: Roschewski, Mark, et al.
Publicado: (2020)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States
por: Alrawashdh, Neda, et al.
Publicado: (2022)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
por: Wang, Qi, et al.
Publicado: (2015)

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
por: Wang, Qi, et al.
Publicado: (2019)

Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation
por: Roman-Garcia, Sara, et al.
Publicado: (2018)

Bruton’s tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia
por: Nimmagadda, S C, et al.
Publicado: (2018)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
por: Martin, Elodie, et al.
Publicado: (2020)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
por: Rule, Simon A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m64uhgr0bivh6ougaq54s7mpo0